AGS 534
Alternative Names: AGS-534Latest Information Update: 25 Mar 2022
At a glance
- Originator Ben Gurion University
- Developer Neuromagen Pharma
- Class Infertility therapies; Small molecules
- Mechanism of Action Telomerase activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Infertility
- Discontinued Neurodegenerative disorders
Most Recent Events
- 25 Mar 2022 Discontinued for Neurodegenerative disorders in Israel (unspecified route) Not mentioned on current pipeline (Neuromagen Pharma pipeline March 2022)
- 22 Mar 2022 Preclinical trials in Infertility in Israel (unspecified route) (Neuromagen Pharma pipeline, March 2022)
- 03 Nov 2021 Early research in Neurodegenerative disorders in Israel (unspecified route) (Neuromagen Pharma pipeline, November 2021)